Label: information for the user
Isentress 25mgchewable tablets
Isentress 100mg chewable tablets
raltegravir
Read this label carefully before starting to take this medication, as it contains important information for you.
If you are the parent of a child taking Isentress, please read this information carefully with your child.
other people, even if they have the same symptoms as you, as it may harm them.
Even if they are not listed in this label. See section4.
What is Isentress
Isentress contains the active ingredient raltegravir. Isentress is an antiviral medication that acts against the human immunodeficiency virus (HIV). This is the virus that causes acquired immunodeficiency syndrome (AIDS).
How Isentress works
The virus produces an enzyme called HIV integrase, which helps the virus to enter the body's cells and multiply. Isentress prevents this enzyme from functioning. When used with other medications, Isentress can reduce the amount of HIV in the blood (this is known as its "viral load") and increase the count of CD4 cells (a type of white blood cell that plays an important role in maintaining a healthy immune system to help fight infection). By reducing the amount of HIV in the blood, it may improve the functioning of the immune system. This means that the body can fight better against infection.
When to use Isentress
Isentress is used to treat patients who are infected with HIV. Your doctor has prescribed Isentress to help you control the HIV infection you have.
Do not take Isentress:
Warnings and precautions
Consult your doctor, pharmacist, or nurse before starting to take Isentress.
Remember that Isentress does not cure HIV infection. This means that you may still experience infections or other HIV-related illnesses. You should continue to see your doctor regularly while taking this medication.
Mental health problems
Inform your doctor if you have a history of depression or mental illness. Depression, including suicidal thoughts and behaviors, has been observed in some patients taking this medication, especially those with a prior history of depression or mental illness.
Bone problems
Some patients taking combination antiretroviral therapy may develop a bone disease called osteonecrosis (bone tissue death caused by loss of blood supply to the bone). Factors that may increase the risk of developing this disease include the duration of antiretroviral therapy, use of corticosteroids, alcohol consumption, severe immunosuppression, increased body mass index, and others. Signs of osteonecrosis include joint stiffness, pain, and difficulty moving, especially in the hip, knee, and shoulder. If you experience any of these symptoms, see your doctor.
Liver problems
Inform your doctor, pharmacist, or nurse if you have had liver problems in the past, including hepatitis B or C. Your doctor may assess the severity of your liver disease before deciding whether you can take this medication.
Infections
If you notice any symptoms of infection, such as fever and/or feeling unwell, inform your doctor, pharmacist, or nurse immediately. Some patients with advanced HIV infection and a history of opportunistic infections may experience signs and symptoms of inflammation due to previous infections shortly after starting HIV treatment. These symptoms are believed to result from the improvement of the body's immune response, allowing the body to fight off infections that may have been present but not causing obvious symptoms.
In addition to opportunistic infections, autoimmune disorders (a condition that occurs when the immune system attacks healthy body tissue) may also occur after starting HIV treatment. These disorders can occur many months after starting treatment. If you notice any symptoms of infection or other symptoms such as muscle weakness, weakness starting in the hands and feet and ascending to the body trunk, palpitations, tremors, or hyperactivity, inform your doctor immediately to receive necessary treatment.
Muscle problems
Contact your doctor, pharmacist, or nurse immediately if you notice unexplained muscle pain, sensitivity to pressure, or muscle weakness during treatment with this medication.
Skin problems
Contact your doctor immediately if you experience a rash. Severe and potentially life-threatening skin reactions and allergic reactions have been reported in some patients taking this medication.
Other medications and Isentress
Inform your doctor or pharmacist if you are taking, have taken recently, or may need to take any other medication with or without a prescription.
Isentress may interact with other medications.
Inform your doctor, pharmacist, or nurse if you are taking, have taken recently, or may need to take:
Taking Isentress with food and drinks
See section3.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, or think you may be pregnant, consult your doctor or pharmacist before using this medication.
If you are pregnant or breastfeeding, consult your doctor, pharmacist, or nurse before using any medication.
Driving and operating machinery
Do not operate machinery, drive, or ride a bike if you feel dizzy after taking this medication.
Isentress 25mg chewable tablet
Isentress 25mg chewable tablet contains fructose
This medication contains up to 0.54mg of fructose in each tablet.
Fructose may damage teeth.
Isentress 25mg chewable tablet contains sorbitol
This medication contains up to 1.5mg of sorbitol (E420) in each tablet.
Isentress 25mg chewable tablet contains sucrose
This medication contains up to 3.5mg of sucrose in each 25mg chewable tablet.
Sucrose may harm teeth.
If your doctor has told you that you have an intolerance to certain sugars, consult with them before taking this medication.
Isentress 25mg chewable tablet contains aspartame
This medication contains up to 0.47mg of aspartame (E951) in each 25mg chewable tablet, equivalent to up to 0.05mg of phenylalanine.Aspartame contains a source of phenylalanine that may be harmful in cases of phenylketonuria (PKU),a rare genetic disorder in which phenylalanine accumulates due to the body's inability to eliminate it correctly.
Isentress 25mg chewable tablet contains sodium
This medication contains less than 1mmol of sodium (23mg) per tablet; essentially "sodium-free".
Isentress 100mg chewable tablet
Isentress 100mg chewable tablet contains fructose
This medication contains up to 1.07mg of fructose in each tablet.
Fructose may damage teeth.
Isentress 100mg chewable tablet contains sorbitol
This medication contains up to 2.9mg of sorbitol (E420) in each tablet.
Isentress 100mg chewable tablet contains sucrose
This medication contains up to 7mg of sucrose in each 100mg chewable tablet.
Sucrose may harm teeth.
If your doctor has told you that you have an intolerance to certain sugars, consult with them before taking this medication.
Isentress 100mg chewable tablet contains aspartame
This medication contains up to 0.93mg of aspartame (E951) in each 100mg chewable tablet, equivalent to up to 0.10mg of phenylalanine.Aspartame contains a source of phenylalanine that may be harmful in cases of phenylketonuria (PKU),a rare genetic disorder in which phenylalanine accumulates due to the body's inability to eliminate it correctly.
Isentress 100mg chewable tablet contains sodium
This medication contains less than 1mmol of sodium (23mg) per tablet; essentially "sodium-free".
Follow exactly the administration instructions of this medication as indicated by your doctor, pharmacist, or nurse. In case of doubt, consult your doctor, pharmacist, or nurse again. Isentress should be used in combination with other medications for HIV infection.
The 100 mg chewable tablet can be divided into two equal halves. However, it should be avoided breaking the tablets whenever possible.
How much to take
Dose for children between 2 and 11 years of age
Your doctor will recommend the appropriate dose of chewable tablets based on the child's age and weight. This dose should not exceed 300 mg twice a day. Your doctor will tell you how many chewable tablets the child should take.
Isentress is also available in 400 mg tablets, 600 mg tablets, and oral granules for suspension.
Do not interchange between the chewable tablet, oral granules for suspension, 600 mg tablet, or 400 mg tablet without consulting your doctor, pharmacist, or nurse first.
Children should attend scheduled visits with their doctor as their Isentress dose should be adjusted as they grow, gain weight, or become older. Your doctor may also want to prescribe the 400 mg tablet when they are able to swallow a tablet.
This medication can be taken with or without food or beverages.
If you take more Isentress than you should
Do not take more tablets than your doctor has recommended. If you take more tablets than recommended, consult your doctor.
If you forget to take Isentress
If you interrupt treatment with Isentress
It is essential that you take Isentress exactly as your doctor has told you.Do not change the dose or stop taking this medication without consulting your doctor, pharmacist, or nurse first.Do not stop taking it, because:
If you have any other questions about the use of this medication, ask your doctor, pharmacist, or nurse.
Like all medicines, this medicine can cause side effects, although not everyone will experience them.
Severe side effects–these are rare (may affect up to 1 in 100people)
Seek medical attention immediately if you notice any of the following side effects:
Seek medical attention immediately if you notice any of the side effects mentioned above.
Frequent:the following side effects may affect up to 1 in 10people
Poorly frequent: the following side effects may affect up to 1 in 100people
Other side effects in children and adolescents
Reporting side effects
If you experience any type of side effect, consult your doctor, pharmacist, or nurse, even if it is a possible side effect that does not appear in this prospectus.You can also report them directly through thenational notification system included in theAppendixV. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Medications should not be disposed of through drains or in the trash. Ask your pharmacist how to dispose of the containers and medications that you no longer need. This will help protect the environment.
Isentress Composition
The active ingredient is raltegravir.
25 mg chewable tablets:
Each chewable tablet contains 25 mg of raltegravir (potassium).
The other components are: hydroxypropylcellulose, sucralose, sodium saccharin, sodium citrate dihydrate, mannitol (E 421), yellow iron oxide, glycirricinamide, sorbitol (E 420), fructose, natural and artificial flavors (orange, banana, and masking), aspartame (E 951), sucrose, crospovidone Type A, magnesium stearate, sodium stearate fumarate, ethylcellulose 20 cP, ammonium hydroxide, medium-chain triglycerides, oleic acid, hypromellose 2910/6 cP, and macrogol/PEG 400.
100 mg chewable tablets:
Each chewable tablet contains 100 mg of raltegravir (potassium).
The other components are: hydroxypropylcellulose, sucralose, sodium saccharin, sodium citrate dihydrate, mannitol (E 421), red iron oxide, yellow iron oxide, glycirricinamide, sorbitol (E 420), fructose, natural and artificial flavors (orange, banana, and masking), aspartame (E 951), sucrose, crospovidone Type A, magnesium stearate, sodium stearate fumarate, ethylcellulose 20 cP, ammonium hydroxide, medium-chain triglycerides, oleic acid, hypromellose 2910/6 cP, and macrogol/PEG 400.
Appearance of the product and contents of the package
Isentress 25 mg chewable tablets:
Chewable tablet of yellowish color, with orange and banana flavor, round, with the MSD corporate logo on one face and "473" on the other face.
Available in one package size: 1 bottle with 60 tablets. The bottle contains a desiccant.
Isentress 100 mg chewable tablets:
Chewable tablet of orange-yellowish color, with orange and banana flavor, oval, scored on both faces, engraved on one face with the MSD corporate logo and the inscription "477" and without inscription on the other face.
Available in one package size: 1 bottle with 60 tablets. The bottle contains a desiccant.
Holder of the marketing authorization and responsible for manufacturing
Merck Sharp & Dohme B.V.
Waarderweg 39
2031 BN Haarlem
Netherlands
For more information about this medicine, please contact the local representative of the marketing authorization holder:
België/Belgique/Belgien MSD Belgium Tél/Tel: +32(0)27766211 | Lietuva UAB Merck Sharp & Dohme Tel.:+37052780247 |
Luxembourg/Luxemburg MSD Belgium Tél/Tel: +32(0)27766211 | |
Ceská republika Merck Sharp & Dohmes.r.o. Tel.:+420233010111 | Magyarország MSD Pharma Hungary Kft. Tel.:+36 18885300 |
Danmark MSD Danmark ApS Tlf: +45 4482 4000 | Malta Merck Sharp& Dohme Cyprus Limited Tel:8007 4433 (+356 99917558) |
Deutschland MSD Sharp & Dohme GmbH Tel:0800 673 673 673 (+49 (0) 89 4561 0) e-mail@msd.de | Nederland Merck Sharp & Dohme B.V. Tel: 0800 9999000 (+31 23 5153153) |
Eesti Merck Sharp & Dohme OÜ Tel.: +3726144 200 | Norge MSD (Norge) AS Tlf: +47 32 20 73 00 |
Ελλ?δα MSD Α.Φ.Β.Ε.Ε. Τηλ: + 30 210 98 97 300 | Österreich Merck Sharp & Dohme Ges.m.b.H. Tel: +43 (0) 1 26 044 dpoc_austria@merck.com |
España Merck Sharp & Dohme de España, S.A. Tel: +34 91 321 06 00 | Polska MSD Polska Sp.z o.o. Tel.:+48225495100 |
France MSD France Tél: + 33 (0) 1 80 46 40 40 | Portugal Merck Sharp & Dohme, Lda Tel:+351 21 4465700 |
Hrvatska Merck Sharp & Dohme d.o.o. Tel: + 385 1 6611 333 | România Merck Sharp & Dohme Romania S.R.L. Tel: +40 21 529 29 00 |
Ireland Merck Sharp & Dohme Ireland (Human Health) Limited Tel: +353 (0)1 2998700 | Slovenija Merck Sharp & Dohme, inovativna zdravila d.o.o. Tel:+38615204201 |
Ísland Vistor hf. Sími: +354 535 7000 | Slovenská republika Merck Sharp & Dohme, s. r. o. Tel.:+421258282010 |
Italia MSD Italia S.r.l. Tel: 800 23 99 89 (+39 06 361911) | Suomi/Finland MSD Finland Oy Puh/Tel: +358 (0) 9 804 650 |
Κ?προς Merck Sharp & Dohme Cyprus Limited Τηλ:800 00 673 (+35722866700) | Sverige Merck Sharp & Dohme (Sweden) AB Tel: +46 77 5700488 |
Latvija SIA Merck Sharp & Dohme Latvija Tel:+37167364224 | United Kingdom(Northern Ireland) Merck Sharp & Dohme Ireland (Human Health) Limited Tel: +353 (0)1 2998700 |
Last revision date of this leaflet:<{MM/AAAA}><{mes AAAA}>.
For detailed information about this medicine, please visit the European Medicines Agency website:http://www.ema.europa.eu.
Маєте питання щодо цього лікування або ваших симптомів? Зв'яжіться з ліцензованим лікарем для отримання допомоги та персонального догляду.